We are live on ! Find out more
KXA

KPCB XIII Associates Portfolio holdings

AUM $186M
1-Year Est. Return 11.23%
This Fund
S&P 500
This Quarter Est. Return
-7.06%
1 Year Est. Return
-11.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$501M
AUM Growth
-$42M
Cap. Flow
+$669K
Cap. Flow %
0.13%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RPID icon
Rapid Micro Biosystems
RPID
+$669K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNY icon
1
Progyny
PGNY
$2.4B
$415M 82.73%
7,406,115
– –
LUNG icon
2
Pulmonx
LUNG
$51.5M
$35.8M 7.14%
994,971
– –
TMDX icon
3
Transmedics
TMDX
$2.46B
$30.5M 6.09%
923,221
– –
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$19.7M 3.92%
3,838,166
– –
RPID icon
5
Rapid Micro Biosystems
RPID
$99.1M
$598K 0.12%
+32,400
New +$669K

Similar funds

BC
Bullfrog Capital Palo Alto, California $191M AUM 19.3% 1-Year Est. Return
CC
Claybrook Capital Wellesley, Massachusetts $175M AUM 10.74% 1-Year Est. Return
BAG
Briggs Advisory Group Lincoln, Rhode Island $175M AUM 16.29% 1-Year Est. Return
SWA
Sutton Wealth Advisors Tampa, Florida $203M AUM 20.54% 1-Year Est. Return
DLG
Daniel L. Goodwin $207M AUM 22.03% 1-Year Est. Return
NFAM
North Fourth Asset Management Englewood Cliffs, New Jersey $164M AUM 43.6% 1-Year Est. Return
RCGI
Ribbit Capital GP III Palo Alto, California $211M AUM 51.22% 1-Year Est. Return
TA
Trellis Advisors Ellensburg, Washington $219M AUM 17.82% 1-Year Est. Return

KPCB XIII Associates's Q3 2021 Portfolio in Review

As of Q3 2021, KPCB XIII Associates held 5 positions worth $501M, down 7.7% from $543M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

KPCB XIII Associates's Q3 2021 filing shows 1 new position. Its largest new stake was Rapid Micro Biosystems: 32,400 shares worth $598K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • KPCB XIII Associates's largest Q3 2021 buy was Rapid Micro Biosystems: 32,400 shares worth $598K.
  • KPCB XIII Associates's ten largest holdings make up 100% of its $501M portfolio in Q3 2021.
  • KPCB XIII Associates opened 1 new position and closed 0 in Q3 2021.
  • KPCB XIII Associates's portfolio value fell 7.7% quarter-over-quarter to $501M.

Based on KPCB XIII Associates's 13F filing for Q3 2021, filed 25 Oct 2021.